Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LianBio stock logo
LIAN
LianBio
$0.20
$0.20
$0.27
$4.99
$21.61M0.231.04 million shs1 shs
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
$0.29
-1.3%
$0.35
$0.24
$3.43
$20.63M0.27456,696 shs306,406 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.15
-1.9%
$2.86
$1.75
$9.37
$5.09M1.66848,860 shs71,385 shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$1.30
$1.68
$1.26
$4.30
$19.77M1.7698,293 shs81,015 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LianBio stock logo
LIAN
LianBio
+4.30%0.00%0.00%+3.52%-36.53%
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
-1.28%-6.73%+15.29%-56.12%-90.49%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+6.07%-8.62%+72.07%+21.62%+2,049.50%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-5.11%-2.99%-13.91%-46.06%-52.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
4.1321 of 5 stars
3.54.00.04.60.62.50.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.3369 of 5 stars
0.05.00.00.00.60.00.0
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
2.761 of 5 stars
3.53.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
3.00
Buy$3.03945.62% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3.00
Buy$6.25380.77% Upside

Current Analyst Ratings Breakdown

Latest SNOA, VYNE, OVID, and LIAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.75 ➝ $4.50
4/24/2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/24/2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
3/12/2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $3.00
3/6/2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.75 ➝ $5.75
2/19/2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.75 ➝ $5.75
(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
$566K36.45N/AN/A$1.24 per share0.23
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.36N/AN/A$3.01 per share1.05
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$501K39.47N/AN/A$6.36 per share0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
-$52.34M-$0.38N/AN/AN/A-5,142.56%-39.24%-26.19%5/13/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$28.45M-$0.94N/AN/AN/A-6,896.55%-43.73%-38.55%N/A

Latest SNOA, VYNE, OVID, and LIAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
-$0.14N/AN/AN/A$0.03 millionN/A
5/8/2025Q1 2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million
3/11/2025Q4 2024
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
-$0.16-$0.13+$0.03-$0.13$0.19 million$0.08 million
3/6/2025Q4 2024
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.31-$0.28+$0.03-$0.28$0.14 million$0.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
0.18
5.66
5.66
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/A
5.81
5.81

Institutional Ownership

CompanyInstitutional Ownership
LianBio stock logo
LIAN
LianBio
74.85%
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
72.24%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
83.78%

Insider Ownership

CompanyInsider Ownership
LianBio stock logo
LIAN
LianBio
7.59%
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
13.30%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
6071.11 million61.57 millionOptionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3015.21 million14.04 millionNot Optionable

Recent News About These Companies

VYNE Therapeutics (VYNE) to Release Earnings on Thursday
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update
VYNE Therapeutics Provides Update on VYN202 Program
H.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)
VYNE Therapeutics reports Q4 EPS (28c) vs (20c) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
LianBio stock logo

LianBio NASDAQ:LIAN

$0.20 0.00 (0.00%)
As of 05/8/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.29 0.00 (-1.33%)
As of 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.15 -0.06 (-1.87%)
As of 04:00 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

VYNE Therapeutics stock logo

VYNE Therapeutics NASDAQ:VYNE

$1.30 0.00 (0.00%)
As of 04:00 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.